Posted by Michael Wonder on 24 Mar 2017
ICER releases draft evidence report on crisaborole and dupilumab for atopic dermatitis
24 March 2017 - Public comment period open until 21 April.
The Institute for Clinical and Economic Review (ICER) has released a draft evidence report assessing the comparative clinical effectiveness of crisaborole (Eucrisa, Pfizer) for treatment of mild-to-moderate atopic dermatitis in adults and children, and the clinical effectiveness and value of and dupilumab (Dupixent, Sanofi and Regeneron) for treatment of moderate to severe atopic dermatitis in adults.
The report, as well as accompanying draft voting questions, is now open to public comment for four weeks.
